Modification of HDL$_3$ by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux

Angela Pirillo [a,*], Patrizia Uboldi [a], Gianluca Pappalardo [a],
Hartmut Kuhn [b], Alberico L. Catapano [a]

[a] *Department of Pharmacological Sciences, Via Balzaretti, 9, 20133 Milano, Italy*
[b] *Institute of Biochemistry, University Medicine Berlin-Charité, Berlin, Germany*

Abstract

Objective: Elevated levels of high-density lipoprotein (HDL) cholesterol are inversely related to the risk of cardiovascular disease. The anti-atherosclerotic function of HDL is mainly ascribed to its role in reverse cholesterol transport, and requires the integrity of HDL structure. Experimental evidence suggests that the ability of HDL to promote removal of excess cholesterol from peripheral cells is impaired upon oxidation. On the other hand, tyrosylation of HDL enhances its protective function, suggesting that not all forms of modified lipoprotein may be atherogenic. In the present study we investigated the effect of a mild oxidation of HDL$_3$ on its function as cholesterol acceptor.

Methods and results: A mild oxidative stress (induced by 15 min exposure of HDL$_3$ to 1 μM Cu^{++} or to 15-lipoxygenase) caused the formation of pre-β-migrating particles. Compared to native lipoprotein, mildly modified HDL$_3$ induced a significant ATP-binding cassette transporter 1 (ABCA1)-mediated increase of cholesterol and phospholipids efflux from J774 macrophages. This effect was abolished by an inhibitor of ABCA1-mediated lipid efflux (glyburide) and was absent in Tangier fibroblasts.

Conclusions: A mild oxidative modification of HDL$_3$ may improve its function as cholesterol acceptor, increasing ABCA1-mediated lipid efflux from macrophages, a process that may reduce foam cell formation.

1. Introduction

A number of studies have established that elevated concentrations of plasma high-density lipoprotein (HDL) reduce the risk for coronary heart disease (CHD) [1–3]. The atheroprotective role of HDL is believed to depend mainly upon its ability to remove cholesterol from peripheral cells, a process known as reverse cholesterol transport [4,5].

Human HDL consists of distinct subfractions that, besides differences in shape, density, size, and charge, differ in the mechanisms by which they promote the removal of cholesterol from cells [6,7]. Among the HDL subfractions, pre-β1-HDL,

which contains apoA-I as only apoprotein and exhibits pre-β electrophoretic mobility, appears to be the most efficient acceptor of cellular cholesterol [7–9], *via* the interaction with ATP-binding cassette transporter 1 (ABCA1) [10–12]. The physiological mechanism by which pre-β1-HDL is generated in plasma is not fully understood, but there are at least two potential sources: i) it may be derived from the interaction of lipid poor apoA-I secreted from liver or intestine with cell membrane lipids [13,14]; ii) it may be formed during the conversion of mature, spherical HDL (α-HDL) [15]. *In vitro*, pre-β1-HDL can be formed following the interaction of free apoA-I with cholesterol-loaded macrophages [16] or fibroblasts [17]. Furthermore, the concentration of pre-β1-HDL is increased under pathophysiological conditions, such as hypercholesterolemia [18], showing a positive correlation

---

* Corresponding author. Tel.: +39 02 50318293; fax: +39 02 50318386.
*E-mail address:* angela.pirillo@unimi.it (A. Pirillo).

Fig. 1. Mild modified HDL_3 increased cholesterol efflux. J774 were labeled with ^3H-cholesterol as described in Methods, then incubated for 6 h with 10 μg/ml of native HDL_3 or HDL_3 modified with Cu^{++} 1 μM or 15-LO for 15 min. Values are mean±SD of 6 independent experiments. *$p < 0.0005$ *vs* native HDL_3.

with LDL concentration [19]; increased amounts of pre-β1-HDL are also present in cholesterol-fed rabbits and mice [20].

The structural integrity of HDL is essential for their function in the reverse cholesterol transport. In fact, severe oxidation may impact the biological role of HDL by impairing their ability to promote cholesterol efflux *in vitro* [21–23]. There is growing pathophysiological evidence that increased generation of reactive oxygen species and oxidative stress participate *in vivo* to pro-atherogenic mechanisms [24–26]. 15-lipoxygenase [27,28], an enzyme that has been implicated in the conversion of native LDL to an atherogenic form [28,29], may contribute to such a mechanism. In a recent paper, we have shown that 15-lipoxygenase-mediated modification of HDL_3 significantly reduces its role as efficient cholesterol acceptor [30].

Data obtained with transgenic rabbits overexpressing 15-lipoxygenase [31,32], however, suggest also anti-atherogenic effects for this enzyme [33]. In this work we studied the functional effect of HDL exposure to a mild oxidative stress, induced by low concentration of copper ions or by 15-lipoxygenase for short periods. These mild modifications caused a transient increase of pre-β-migrating particles from α-HDL_3, generating modified lipoprotein species which exhibited a significantly improved capacity to stimulate reverse cholesterol transport from macrophages.

2. Methods

2.1. Materials

MEM, DMEM, fetal bovine serum (FBS), bovine serum albumin (BSA), 22R-OH cholesterol (22-OH), 9-*cis*-retinoic acid (9cRA), glyburide and Oil red O were from Sigma (St. Louis, MO, USA). ^3H-cholesterol, methyl-^3H-choline chloride, PD10 columns and ECL were from Amersham Biosciences (Uppsala, Sweden). Antiserum anti-human apoA-I was from Dade Behring (Marburg, Germany). SR-BI

blocking antibody was from Abcam (Cambridge, UK). Native reticulocyte-type 15-LO was prepared as described [34]. Cholesterol kit was from Clonital, Italy.

2.2. Cell culture

J774 macrophages were cultured in MEM containing 10% FBS; normal human skin fibroblast and Tangier fibroblasts were cultured in DMEM supplemented with 10% FBS.

2.3. Isolation of plasma lipoproteins

The use of human material in this study conforms to the principles outlined in the Declaration of Helsinki. LDL (d=1.019–1.063 g/ml) and HDL_3 (d=1.125–1.21 g/ml) were isolated from fresh plasma of normolipidemic healthy volunteers by sequential ultracentrifugation [35]. Protein content was determined by the method of Lowry using BSA as standard [36]. LDL were acetylated by repeated additions of acetic anhydride [37].

2.4. Modification of HDL_3

HDL_3 (1 mg/ml) were modified by 15-lipoxygenase (2 μl/ml) [30] or by $CuSO_4$ 1 μM for 15 min up to 24 h at 37 °C. The oxidation was blocked by the addition of 10 μM BHT and by lowering the temperature to 4 °C. The TBARS content and the apoproteins cross-linking in mildly modified HDL_3 were evaluated as previously described [30].

2.5. Agarose gel electrophoresis and western blotting

Aliquots of native and modified HDL_3 were electrophoresed on a 0.8% agarose gel, then transferred onto a nitrocellulose membrane. After blocking with 5% nonfat milk in PBS-T (PBS-0.1% Tween) for 1 h at room temperature, apoA-I was identified using an antiserum anti-human apoA-I from rabbit (1:20000) followed by a goat anti-rabbit IgG peroxidase-conjugated (1:20000). Immuno-complexes were visualized using an ECL western blotting detection system followed by autoradiography.


Fig. 2. Mild oxidative modification of HDL_3 generated pre-β-migrating particles. The distribution of apoA-I in HDL_3 subclasses of native, Cu^{++} 1 μM or 15-LO-modified HDL_3 was analyzed by 0.8% agarose gel electrophoresis, followed by western blotting using an anti-apoA-I antibody.

Fig. 3. Mild modified HDL$_3$ increased ABCA1-mediated cholesterol (A) and phospholipid (B) efflux and decreased total cholesterol content (C). J774 labeled with ^{3}H-cholesterol (A) or methyl-^{3}H-choline chloride (B) were pre-incubated with 22-OH/9cRA (10 μM/1 μM), then incubated for 6 h (A) or 4 h (B) with 10 μg/ml of native HDL$_3$ or HDL$_3$ modified with Cu^{++} 1 μM or 15-LO for 15 min. (C) Quantification of total cholesterol levels in lipid-loaded macrophages after incubation with native or mildly modified HDL$_3$. Values are mean±SD from 6 (A) and 3 (B, C) independent experiments. (A) *$p<0.00005$ vs native HDL$_3$; (B) #$p<0.05$ vs native HDL$_3$.

2.6. Cholesterol efflux experiments

J774 were labeled with ^{3}H-cholesterol (1 μCi/ml) in MEM containing 0.2% BSA and 50 μg/ml AcLDL; after 24 h, cells were washed once with PBS and incubated for 24 h in MEM+0.2% BSA in the absence or the presence of 22-OH/9cRA (10 μM/1 μM). Labeling of fibroblasts was carried out in DMEM containing 1% FBS and ^{3}H-cholesterol (1 μCi/ml); after 24 h cells, cells were washed once with PBS and incubated for 24 h in DMEM +0.2% BSA in the presence of 22-OH/9cRA (10 μM/1 μM).

To induce cholesterol efflux, 10 μg/ml of native HDL$_3$ or HDL$_3$ modified with Cu^{++} 1 μM or 15-LO for 15 min were added to the cells for 6 h. At the end of the experiment, media were collected, centrifuged to remove cellular debris and aliquots were used to quantify the radioactivity content by liquid scintillation. Cell monolayers were lysed in 0.1 NaOH and aliquots were used to determine the intracellular radio-activity content. The ^{3}H-cholesterol release was calculated

as the ratio of radioactivity released in the medium to the medium plus cell (total) radioactivity.

In some experiments, glyburide (1 mM) was added together with the lipoproteins to the medium; alternatively, cells were pre-incubated with a SR-BI blocking antibody (1:1000 dilution) before the incubation with lipoproteins [30].

2.7. Phospholipid efflux experiments

J774 were incubated in MEM containing 0.2% BSA, 50 μg/ml AcLDL and methyl-^{3}H-choline chloride (2 μCi/ml). After 24 h, cells were washed with PBS and incubated for 24 h in MEM+0.2% BSA in the presence of 22-OH/9cRA (10 μM/1 μM). Native HDL$_3$ or HDL$_3$ modified with Cu^{++} 1 μM or 15-LO for 15 min (10 μg/ml) were added to cells for 4 h. At the end of the experiment, media were collected, centrifuged to remove cellular debris and lipids were extracted with hexane:2-propanol (3:2). Radioactivity in the lipid extracts was quantified by liquid scintillation. Cell monolayers were lysed with 0.1N NaOH, lipids were extracted with hexane:2-propanol and aliquots were used to determine the intracellular radioactivity content.

2.8. Purification and modification of α-HDL$_3$ particles

A discontinuous salt density gradient was created in an ultracentrifuge tube. A solution containing 2 mg of HDL$_3$ and 20 mg of BSA was adjusted to $d=1.25$ g/ml by the addition of KBr. Two ml of the obtained solution was placed in a Beckman ultracentrifuge tube and layered with: 2 ml of $d=1.21$ g/ml, 2 ml of $d=1.18$ g/ml, 2 ml of $d=1.16$ g/ml, 1 ml of $d=1.14$ g/ml, 1 ml of $d=1.12$ g/ml and 2 ml of


Fig. 4. Purification (A) and modification (B) of α-migrating particles. (A) α-migrating particles were isolated from HDL$_3$ by a discontinuous salt density gradient (1.11–1.25 g/ml) and ultracentrifugation at 40,000 rpm at 5 °C for 18 h. The distribution of apoA-I in each fraction was determined by 0.8% agarose gel electrophoresis and western blotting using an anti-human apoA-I antiserum. (B) Fractions consisting of purified α-particles were modified with Cu^{++} 1 μM, Cu^{++} 20 μM or 15-LO for the indicated times. After modification, the distribution of apoA-I-containing particles was analysed by 0.8% agarose gel electrophoresis and western blotting.

Fig. 5. Mild modified α-HDL$_3$ increased ABCA1-mediated cholesterol efflux. (A) J774 labeled with ^{3}H-cholesterol were pre-incubated in the absence or the presence of 22-OH/9cRA (10 μM/1 μM), then incubated for 6 h with 10 μg/ml of native α-HDL$_3$ or α-HDL$_3$ modified with Cu^{++} 1 μM or 15-LO for 15 min. Values are mean±SD of 3 experiments performed in duplicates. *$p<0.01$ **$p<0.005$ vs native α-HDL$_3$. (B) α-HDL$_3$ were modified with 15-LO for 15 min, then subjected to a density gradient ultracentrifugation to remove pre-β-particles. Native, mildly modified or re-isolated α-HDL$_3$ (10 μg/ml) were the added to J774 overexpressing ABCA1 to evaluate cholesterol efflux. Values are mean±from 3 independent experiments. 1: native α-HDL$_3$; 2: α-HDL$_3$ modified with 15-LO for 15 min; 3: α-particles reisolated from α-HDL$_3$ modified with 15-LO for 15 min.

$d=1.11$ g/ml. Samples were centrifuged at 40,000 rpm at 5 °C for 18 h in a Beckman SW41 rotor. Twelve fractions (1 ml each) were collected from the top of the tube. To study the distribution of apoA-I in HDL$_3$ particles, aliquots of fractions obtained from the density gradient were subjected to agarose gel electrophoresis and western blotting as described above. Fractions consisting of purified α-particles were retrieved, concentrated in a Centricon filter unit fitted with a YM10 membrane and desalted in PBS using a Sephadex G25 (PD10) column. The protein content was evaluated by the Lowry method. α-HDL$_3$ were modified under the same experimental conditions described for HDL$_3$. After modification, the distribution of apoA-I-containing particles was analyzed by agarose gel electrophoresis and western blotting, as described.

For some experiments, after modification with 15-LO for 15 min, α-HDL$_3$ were centrifuged in a density gradient to remove new formed pre-β-particles, as described above.

2.9. Oil red O staining

Foam cell formation was induced by cholesterol-loading with acetylated LDL (50 μg/ml) for 24 h; after this time, cells

Fig. 6. Glyburide inhibited ABCA1-mediated cholesterol efflux to mildly modified HDL$_3$. ABCA1 overexpressing J774 were incubated for 6 h with 10 μg/ml of native HDL$_3$ or HDL$_3$ modified for 15 min with Cu^{++} 1 μM or 15-LO, in the absence or the presence of glyburide (1 mM) or a SR-BI blocking antibody (1:1000). Values are mean±SD from 3 independent experiments. *$p<0.005$, **$p<0.0005$.

were washed twice with PBS and incubated for 24 h with 100 μg/ml of HDL$_3$ native or modified for 15 min with 15-LO. At the end of the incubation, cells were fixed with 5% paraformaldehyde for 1 h, then neutral lipids were stained with Oil red O (0.2% in isopropanol) for 30 min. Cells were rinsed thrice with water and the stained lipid droplets were visualized by light microscopy. For quantification, the dye was extracted in isopropanol and the absorbance was measured at 515 nm. Cell protein concentration was determined by the method of Lowry and absorbance values were normalized to protein.

2.10. Total cholesterol determination.

After cholesterol-loading with AcLDL (50 μg/ml), cells were incubated for 24 h with 22-OH/9cRA (10 μM/1 μM) to induce ABCA1 expression, then incubated for 6 h with 10 μg/ml HDL$_3$ native or modified for 15 min with 15-LO. Cellular lipids were extracted in hexane/isopropanol (3:2) and cholesterol content was evaluated by a colorimetric assay according to the instructions of the manufacturer and

Fig. 7. Mildly modified HDL$_3$ increased ABCA1-mediated cholesterol efflux in normal fibroblast, but not in Tangier fibroblasts. Normal and Tangier fibroblasts were labeled with ^{3}H-cholesterol, pre-incubated with 22-OH/9cRA (10 μM/1 μM), then incubated for 6 h with 10 μg/ml of native HDL$_3$ or HDL$_3$ modified with Cu^{++} 1 μM or 15-LO for 15 min. Values are mean±SD from 3 independent experiments. *$p<0.05$ vs native HDL$_3$.

normalized by protein concentration, determined by the method of Lowry.

3. Results

In agreement with our previous results [30], the incubation of HDL_3 with low concentrations of Cu^{++} (1 μM) or with 15-LO for 15 min neither increased the lipoprotein TBARS content, nor induced an appreciable apolipoprotein cross-linking (data not shown). However, compared to native lipoprotein, HDL_3 modified for 15 min with Cu^{++} 1 μM or 15-LO induced a higher cholesterol efflux from J774 macrophages (Fig. 1). The increase was independent of the modification type (chemical or enzymatic) and, as expected from previous data [30], disappeared at 24 h. Analysis of HDL_3 particles showed that incubation with Cu^{++} 1 μM or 15-LO for 15 min induced the appearance

of particles with pre-β electrophoretic mobility up to 2 h modification (Fig. 2), undetectable at 24 h (Fig. 2).

We therefore addressed the question as to whether the observed higher cholesterol efflux induced by mildly modified HDL_3 might be related to the increase of pre-β-migrating particles, possibly through ABCA1 activity. To this end, J774 cells were pre-incubated with 22-OH/9cRA to increase ABCA1 expression [30,38]. Accordingly, these cells exhibited a significantly higher cholesterol efflux when incubated with mildly modified HDL_3, compared with cells incubated with native HDL_3 (Fig. 3A). In agreement with this finding, total cholesterol levels were lower in the presence of mildly modified HDL_3 (Fig. 3B).

ABCA1 is involved in the reverse cholesterol transport, but also triggers the efflux of phospholipids to lipid poor apoA-I [39]; for this reason, we studied the impact of mildly modified HDL_3 on this process: in cells overexpressing

Fig. 8. Mildly modified HDL_3 decreased lipid content in J774. Lipid loaded J774 were incubated with 22-OH/9cRA (10 μM/1 μM), then incubated for 24 h with 100 μg/ml of native HDL_3 or HDL_3 modified with 15-LO for 15′. Neutral lipids were stained with Oil red O. (A–D) The stained lipid droplets were visualized by light microscopy. Original magnification, 40×. (E) The dye was extracted with isopropanol and the absorbance was measured at 515 nm; the optical density was corrected for cell protein concentrations. The data are expressed as percentage of lipid-loaded cells (AcLDL), set at 100% for each experiment. Values are mean ±SD from 3 independent experiments. *$p<0.01$ vs native HDL_3.

ABCA1 the incubation with HDL$_3$ modified with Cu^{++} 1 μM or 15-LO for 15 min induced a significant increase in phospholipid efflux compared to native HDL$_3$ (Fig. 3C).

As native HDL$_3$ did already contain a minor fraction pre-β migrating particles (Fig. 2) whose amount was increased after a mild oxidative modification, we aimed at clarifying whether those particles were generated *ex-novo* from α-particles or derived from a conformational rearrangement of pre-β particles already present in native lipoprotein. To this end, α-migrating particles were purified from native HDL$_3$ by density gradient ultracentrifugation (Fig. 4A) and modified under the same experimental conditions described for HDL$_3$. In keeping with the data with whole HDL$_3$, short-term modification of α-HDL$_3$ with Cu^{++} 1 μM or 15-LO generated pre-β-migrating particles up to 2 h, which disappeared at longer incubation periods (Fig. 4B), indicating an *ex-novo* formation of the pre-β particles after mild oxidative modification. A higher concentration of Cu^{++} (20 μM) failed to induce the formation of pre-β particles from α-HDL$_3$ (Fig. 4B). α-HDL$_3$ modified with Cu^{++} 1 μM or 15-LO for 15 min induced, when compared to native α-HDL$_3$, a higher cholesterol efflux from J774 cells under basal conditions (Fig. 5A). In cells overexpressing ABCA1, mildly modified α-HDL$_3$ further stimulated the cholesterol efflux process (Fig. 5A), while no significant effect was found with native α-HDL$_3$. These data suggested that the newly formed pre-β-migrating particles efficiently promoted cholesterol efflux *via* an ABCA1-mediated mechanism; this finding was further confirmed using as cholesterol acceptor isolated pre-β-particles purified by density gradient ultracentrifugation (data not shown).

On the other hand, the removal of pre-β-migrating particles from α-HDL$_3$ modified with 15-LO for 15 min abolished the increased cholesterol efflux obtained with mildly modified α-HDL$_3$ (Fig. 5B), further indicating that pre-β particles were responsible for the observed effect.

To show that ABCA1 activity was actually involved in the increased cholesterol efflux observed with mildly modified HDL$_3$, J774 overexpressing ABCA1 were pre-incubated with glyburide, an inhibitor of ABCA1-mediated lipid efflux to apoA-I [40]. Glyburide reduced the cholesterol efflux to native HDL$_3$ by 36%, and to mild modified HDL$_3$ by ~70% (Fig. 6), indicating an essential contribution of ABCA1 activity in the mildly modified HDL$_3$-induced cholesterol efflux. The presence of a SR-BI blocking antibody, which reduces SR-BI-mediated cholesterol efflux to α-HDL$_3$ [30], could not inhibit cholesterol efflux to mildly modified HDL$_3$ (Fig. 6).

The most direct evidence that ABCA1 transporter is involved in the increased cholesterol efflux induced by pre-β HDL particles generated in mildly modified HDL$_3$ was obtained using Tangier fibroblasts as cellular model. These cells do not express a functional ABCA1 transporter and thus, the pre-β particles-induced cholesterol efflux is predicted to be absent [41]. As expected, modification of α-HDL$_3$ with Cu^{++} 1 μM or 15-LO for 15 min caused an increase in cholesterol efflux from normal fibroblasts pretreated with 22-OH/9cRA to overexpress ABCA1 (Fig. 7). In contrast, under the same experimental conditions, Tangier fibroblasts did not show a stimulatory effect on cholesterol release in the presence of mildly modified HDL$_3$ (Fig. 7).

Finally, mildly modified HDL$_3$ were tested for the ability to reduce foam cell formation. After loading with AcLDL, J774 exhibited extensive Oil red O staining (Fig. 8B, E) compared to unloaded cells (Fig 8A). As expected, native HDL$_3$ significantly reduced neutral lipid content (Fig. 8C, E); HDL$_3$ modified for 15 min with 15-LO further decreased cell lipid content (Fig 8D, E).

4. Discussion

Lipoproteins modification is usually regarded as a deleterious process, which affects their physiological properties, triggering events that can promote atherogenesis. HDL modification impairs its ability to promote cholesterol efflux from cultured cells, suggesting that changes in the protein and/or lipid moiety alter the athero-protective role of HDL [21–23,30]. Not all modification of HDL, however, shift HDL towards a pro-atherogenic particle. Tyrosylation, for instance, enhances the removal of cholesterol from cultured fibroblasts and macrophages [42] and the administration of tyrosylated HDL to apo-E-deficient mice induces a significant decrease of atherosclerotic lesions [43]. The mechanism by which tyrosylated HDL exerts its protective role seems to be independent of passive cholesterol desorption from the cell membrane, suggesting a possible involvement of ABCA1 activity [44]. These observations suggest that lipoprotein modification does not always confer pro-atherogenic properties. In the present work we show that mild oxidative modification (enzymatic or non-enzymatic) of HDL$_3$ enhances its ability to induce cholesterol efflux from cells and provides evidence that newly formed pre-β-HDL$_3$ are responsible for this effect through the interaction with ABCA1.

Experimental evidence suggests that oxidative stress represents a key factor in the initiation of vascular dysfunctions associated with atherosclerosis. Both systemic factors, such as hypercholesterolemia [45] and local factors, such as activation of macrophages and T-cells, may contribute to oxidative stress [26]; diet-induced atherosclerosis in different animal models is related, in fact, to an enhanced xanthine oxidase activity and ROS production [45,46]. The tight regulation of both production and removal of reactive oxygen species induces transient fluctuations in oxidant levels modulating gene expression and thus, metabolic switches [47]. Extracellular stimuli like angiotensin II or TNFα [48,49], or pathophysiological conditions such as hypercholesterolemia can shift the balance to a pro-oxidant state, resulting in a decreased activity of antioxidant enzymes (SOD, catalase, GPx) and in lipoprotein modification. Copper is normally tightly sequestered in biological

system and is not readily available as oxidation catalyst. Nevertheless, pro-oxidant forms of copper may be present in circulation and in artery wall of human atherosclerotic lesions [50]. In addition, ROS may be generated through processes mediated by different enzymes such as lipoxygenases [51]. Specifically, 15-lipoxygenase can induce oxidative modification of LDL, rendering them pro-atherogenic [29]. Experimental evidence support such proatherogenic activity of this enzyme [52,53]. On the other hand, data obtained with transgenic rabbits overexpressing 15-lipoxygenase in monocytes/macrophages suggest an antiatherogenic effect [32,33]. Thus, the enzyme may exhibit a dual role in LDL metabolism during atherogenesis (pro- and anti-atherogenic activity). Similarly, our previous results [30] and the data presented in this study suggest a dual activity of 15-lipoxygenase on HDL. In early stages of HDL modification, production of pre-β-migrating particles might result in an anti-atherogenic role, with an improvement of HDL-mediated reverse cholesterol transport, thus resulting in a reduced cellular cholesterol content. A crucial role for the interaction between pre-β-migrating particles formed in mild modified HDL_3 and ABCA1 can be assumed, as suggested by experiments using an ABCA1 inhibitor or Tangier fibroblasts expressing a non-functional form of ABCA1 [41]. At later time points, when HDL particles are converted into more extensively modified species, the cholesterol accepting properties are lost [30] and reverse cholesterol transport is impaired. This effect may contribute *in vivo* to the formation of lipid-laden foam cells.

The data obtained in the present study suggest also that pre-β-migrating particles detected in mildly oxidized HDL_3 were generated *ex-novo* from α-particles and did not derive from a conformational change of apoA-I in the pre-β-HDL already present in the lipoprotein preparation. This finding is supported by the observation that oxidation of lipid-bound apoA-I significantly decreases its stability [54]; destabilized apoA-I can be readily released from HDL, providing a pool of lipid-free/lipid-poor apoA-I that exhibits a pre-β electrophoretic mobility. When oxidation proceeds, apoA-I becomes further oxidized, thus increasing the negative particle charge, and this could explain the loss of pre-β-migrating particles observed by agarose gel electrophoresis. Moreover, an extensive HDL_3 oxidation leads to an increased particles size (not shown) with a reduced ABCA1-mediated cholesterol efflux.

In hypercholesterolemic subjects plasma level of pre-β1-HDL is increased [18,55]. Moreover, sera from patients with low HDL cholesterol, such as in hypertriglyceridemic, trigger a significant increase in cholesterol efflux from J774 cells overexpressing ABCA1, when compared to normolipidemic controls [55]. This effect was attributed to the increased levels of pre-β-HDL particles in hypertriglyceridemic serum. Since hypercholesterolemia is associated with an increased oxidative potential [45,56], the processes investigated here might be of pathophysiological relevance *in vivo*, as our data indicate that pre-β-migrating particles can be formed by mild oxidative modification of HDL_3. Whether pre-β-particles generated under our experimental conditions are structurally related to those detected in hypercholesterolemic plasma remains to be addressed. We can only suggest a common ABCA1-mediated mechanism of cholesterol efflux.

Taken together these data are consistent with the hypothesis that mild oxidative modification of HDL, which leads to the formation of pre-β-HDL migrating particles, might be considered an anti-atherogenic process enhancing reverse cholesterol transport and thus, impairing intracellular lipid deposition in peripheral cells. However, when oxidation proceeds further, HDL lose their cholesterol effluxing properties [30]. These results provide additional evidence for the previous suggestion [57] that a low degree of oxidation is needed for a balanced steady state of lipid metabolism. Deviations in either direction might induce cascades leading to intracellular lipid deposition. Moreover, these results may also contribute to explain the clinical failure of antioxidant therapy in cardiovascular disease [58–60].

Acknowledgments

References

[1] Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107–13.

[2] Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86:19L–22L.

[3] Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108–13.

[4] Rader DJ, Maugeais C. Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. Mol Med Today 2000;6: 170–5.

[5] Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999;144: 285–301.

[6] Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem (Tokyo) 1994;116:257–62.

[7] Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988;27:25–9.

[8] Huang Y, von Eckardstein A, Assmann G. Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb 1993;13:445–58.

[9] Barrans A, Jaspard B, Barbaras R, Chap H, Perret B, Collet X. Pre-beta HDL: structure and metabolism. Biochim Biophys Acta 1996;1300:73–85.

[10] Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712–9.

[11] Oram JF. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 2003;23: 720–7.

[12] Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:1178–84.

[13] Dixon JL, Ginsberg HN. Hepatic synthesis of lipoproteins and apolipoproteins. Semin Liver Dis 1992;12:364–72.

[14] Danielsen EM, Hansen GH, Poulsen MD. Apical secretion of apolipoproteins from enterocytes. J Cell Biol 1993;120:1347–56.

[15] Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999;145: 227–38.

[16] Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 1991;266:3080–6.

[17] Bielicki JK, Johnson WJ, Weinberg RB, Glick JM, Rothblat GH. Efflux of lipid from fibroblasts to apolipoproteins: dependence on elevated levels of cellular unesterified cholesterol. J Lipid Res 1992;33:1699–709.

[18] Miida T, Nakamura Y, Inano K, Matsuto T, Yamaguchi T, Tsuda T, et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem 1996;42:1992–5.

[19] Miida T, Ozaki K, Murakami T, Kashiwa T, Yamadera T, Tsuda T, et al. Prebeta1-high-density lipoprotein (prebeta1-HDL) concentration can change with low-density lipoprotein-cholesterol (LDL-C) concentration independent of cholesteryl ester transfer protein (CETP). Clin Chim Acta 2000;292:69–80.

[20] Sugano M, Makino N, Yanaga T. Effects of hepatic HDL-related mRNAs on plasma pre-beta HDL in cholesterol-fed rabbits. Artery 1997;22: 182–205.

[21] Rifici VA, Khachadurian AK. Oxidation of high density lipoproteins: characterization and effects on cholesterol efflux from J774 macrophages. Biochim Biophys Acta 1996;1299:87–94.

[22] Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem 2002;277: 32172–9.

[23] Suc I, Brunet S, Mitchell G, Rivard GE, Levy E. Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptors, classes A and B. J Cell Sci 2003;116: 89–99.

[24] Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87: 840–4.

[25] Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A–11A.

[26] Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem 2001;82:674–82.

[27] Kuhn H, Heydeck D, Hugou I, Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest 1997;99: 888–93.

[28] Funk CD, Cyrus T. 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc Med 2001;11:116–24.

[29] Chisolm III GM, Hazen SL, Fox PL, Cathcart MK. The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms. J Biol Chem 1999;274:25959–62.

[30] Pirillo A, Uboldi P, Kuhn H, Catapano AL. 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI-and ABCA1-dependent cholesterol efflux from macrophages. Biochim Biophys Acta 2006;1761: 292–300.

[31] Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, et al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996;98:2201–8.

[32] Trebus F, Heydeck D, Schimke I, Gerth C, Kuhn H. Transient experimental anemia in cholesterol-fed rabbits induces systemic overexpression of the reticulocyte-type 15-lipoxygenase and protects from aortic lipid deposition. Prostaglandins Leukot Essent Fatty Acids 2002;67: 419–28.

[33] Cathcart MK, Folcik VA. Lipoxygenases and atherosclerosis: protection versus pathogenesis. Free Radic Biol Med 2000;28: 1726–34.

[34] Belkner J, Stender H, Kuhn H. The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E. J Biol Chem 1998;273:23225–32.

[35] Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345–53.

[36] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75.

[37] Basu SK, Goldstein JL, Anderson GW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A 1976;73:3178–82.

[38] Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524–9.

[39] Smith JD, Le Goff W, Settle M, Brubaker G, Waelde C, Horwitz A, et al. ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I. J Lipid Res 2004;45:635–44.

[40] Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 2001;276:23742–7.

[41] Bertolini S, Pisciotta L, Seri M, Cusano R, Cantafora A, Calabresi L, et al. A point mutation in ABC1 gene in a patient with severe premature coronary heart disease and mild clinical phenotype of Tangier disease. Atherosclerosis 2001;154:599–605.

[42] Francis GA, Oram JF, Heinecke JW, Bierman EL. Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry 1996;35: 15188–97.

[43] Macdonald DL, Terry TL, Agellon LB, Nation PN, Francis GA. Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:1583–8.

[44] Bergt C, Oram JF, Heinecke JW. Oxidized HDL: the paradox-idation of lipoproteins. Arterioscler Thromb Vasc Biol 2003;23:1488–90.

[45] Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546–51.

[46] Kumar SA, Sudahar V, Varalakshmi P. Oxidative renal injury and lipoprotein oxidation in hypercholesterolemic atherogenesis: Role of eicosapentaenoate-lipoate (EPA-LA) derivative. Prostaglandins Leukot Essent Fatty Acids 2006;75:25–31.

[47] Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000;20:2175–83.

[48] Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res 1999;85:23–8.

[49] Visner GA, Chesrown SE, Monnier J, Ryan US, Nick HS. Regulation of manganese superoxide dismutase: IL-1 and TNF induction in pulmonary artery and microvascular endothelial cells. Biochem Biophys Res Commun 1992;188: 453–62.

[50] Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 1995;368:513–5.

[51] Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J Clin Invest 1999;103:1487–8.

[52] Sun D, Funk CD. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase

pathway and diminished oxidation of low density lipoprotein. J Biol Chem 1996;271:24055–62.

[53] Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001;103:2277–82.

[54] Sigalov AB, Stern LJ. Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles. Chem Phys Lipids 2001;113:133–46.

[55] Fournier N, Francone O, Rothblat G, Goudouneche D, Cambillau M, Kellner-Weibel G, et al. Enhanced efflux of cholesterol from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects. Atherosclerosis 2003;171:287–93.

[56] Stokes KY, Cooper D, Tailor A, Granger DN. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 2002;33:1026–36.

[57] Williams KJ, Fisher EA. Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory? Curr Opin Clin Nutr Metab Care 2005;8:139–46.

[58] Kuller LH. A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arterioscler Thromb Vasc Biol 2001;21:1253.

[59] Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A. Antioxidant vitamins and lipid therapy: end of a long romance? Arterioscler Thromb Vasc Biol 2002;22:1535–46.

[60] Zureik M, Galan P, Bertrais S, Mennen L, Czernichow S, Blacher J, et al. Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arterioscler Thromb Vasc Biol 2004;24:1485–91.